Technology Based on Pancreatic Enzyme Therapy

Our long-term therapy is based on a pancreatic proenzyme formulation that suppresses tumor recurrence and metastasis.

How Our Technology Works

Halting Cancer Cells’ Ability to Invade and Metastasize

PRP, our lead candidate, controls cancer cell migration, inhibits tumor blood vessel formation and triggers the cell’s death.

How PRP Works

Latest Developments

Propanc commences investigational medicinal product manufacture of PRP for First-In-Human studies

Propanc successfully completes GLP-compliant 28-day repeat-dose toxicity study for PRP

Significant Market Opportunity for Cancer Therapy

80% of all cancers are solid tumors. We are initially targeting pancreatic, ovarian and colorectal tumors.

View the market need for solid tumors

Stock Information | View Detailed Stock Info

OTCQB: PPCB Propanc Biopharma, Inc.
Day Range
52 Week Range

BIO CEO & Investor Conference Presentation

Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates